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A B S T R A C T
Anorexia nervosa (AN) is a severe psychiatric disorder with high mortality and relapse rates. Even though
changes in inflammatory markers and cytokines are known to accompany cachexia associated with somatic
disorders such as cancer and chronic kidney disorder, studies on inflammatory markers in AN are rare and
typically include few individuals. Here, we utilize an Olink Proteomics inflammatory panel to explore the
concentrations of 92 preselected inflammation-related proteins in plasma samples from women with active AN
(N = 113), recovered from AN (AN-REC, N = 113), and normal weight healthy controls (N = 114). After
correction for multiple testing, twenty-five proteins differed significantly between the AN group and controls
(lower levels: ADA, CCL19, CD40, CD5, CD8A, CSF1, CXCL1, CXCL5, HGF, IL10RB, IL12B, 1L18R1, LAP TGFß1,
MCP3, OSM, TGFα, TNFRSF9, TNFS14 and TRANCE; higher levels: CCL11, CCL25, CST5, DNER, LIFR and OPG).
Although more than half of these differences (N = 15) were present in the comparison between AN and AN-REC,
no significant differences were seen between AN-REC and controls. Furthermore, twenty-five proteins correlated
positively with BMI (ADA, AXIN1, CASP8, CD5, CD40, CSF1, CXCL1, CXCL5, EN-RAGE, HGF, IL6, IL10RB,
IL12B, IL18, IL18R1, LAP TGFß1, OSM, SIRT2, STAMBP, TGFα, TNFRSF9, TNFS14, TRANCE, TRAIL and
VEGFA) and four proteins correlated negatively with BMI (CCL11, CCL25, CCL28 and DNER).
These results suggest that a dysregulated inflammatory status is associated with AN, but, importantly, seem to
be confined to the acute illness state.
1. Introduction
Anorexia nervosa (AN) is a severe psychiatric disorder with high
mortality and relapse rates (Berends et al., 2018). In fact, up to 10% of
those affected die as consequence of the disorder, making it among the
most lethal of the psychiatric disorders (Papadopoulos et al., 2009). AN
is characterized by persistent restriction of energy intake leading to
severe underweight, combined with body image disturbances, and in-
tense fear of gaining weight. The disorder is often accompanied by
behaviours that interfere with weight gain, e.g., purging or extreme
physical activity (Association, 2013; Schaumberg, 2017). Twin studies
have identified a strong genetic contribution: 58–70% of variance in
liability is due to additive genetic factors (Bulik, 2006), and the latest
genome-wide association study (GWAS) has identified eight loci asso-
ciated with AN (Watson, 2019). In addition to genetic factors, en-
vironmental and neurobiological factors are known to contribute to the
etiology of AN (Schaumberg, 2017). Despite this, the pathophysiology
underlying AN is still poorly understood, which makes the development
of treatments challenging. To date, no medications exist that effectively
target the core biology of the disorder and evidence based treatments
are psychotherapeutic in nature.
Although it is widely accepted that inflammation plays an important
role in several psychiatric disorders, the role of inflammatory processes
in AN is still unclear. Changes in body weight and starvation are
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accompanied by changes in a number of inflammatory markers, ren-
dering it difficult to separate starvation-related from disease-related
changes in inflammatory markers. Whilst it is well known that obesity
leads to a pro-inflammatory state (Saltiel and Olefsky, 2017), cachexia
associated with somatic disorders such as cancer (Tan and Fearon,
2008) and chronic kidney disorder (Pecoits-Filho et al., 2003) is also
associated with changes in inflammatory markers and cytokines. In
cachexia, in particular, elevated levels of interleukin (IL) 1 and 6, and
tumor necrosis factorα (TNFα) have been well documented (Fearon
et al., 2012; Patel and Patel, 2017).
In a narrative review, Gibson and Mehler concluded that AN is as-
sociated with dysregulation of the immune system, with an elevated
CD4/CD8 ratio, increased T cell proliferation, an inflammatory profile
that differs from that seen in primary malnutrition, as well as changed
concentrations of a number of pro-inflammatory cytokines (Gibson and
Mehler, 2019). Indeed, two previous meta-analyses have found that
TNFα, IL1ß, IL6, and TNF-receptor-II are significantly increased in AN,
whereas C-reactive protein and the IL6-receptor are significantly de-
creased compared to healthy controls (Solmi, 2015; Dalton, 2018). In
addition, a study of the genetic correlation between several psychiatric
disorders and inflammatory disorders revealed a significant negative
genetic correlation between AN and the acute phase reactant CRP, in-
dicating that people with increased genetic risk for AN are more likely
to carry genetic variants associated with lower levels of CRP (Tylee,
2018). However, even if several other psychiatric disorders (e.g.,
ADHD, major depressive disorder, bipolar disorder, and schizophrenia)
show positive genetic correlations with inflammatory disorders, this
does not seem to be the case with AN (Tylee, 2018).
The aim of this study was to test the hypothesis of a dysregulated
immune system in AN, and whether potential alterations in in-
flammatory markers are state dependent. To these ends, we utilized the
Olink Proteomics inflammation panel to assess concentrations of 92
preselected inflammation-related proteins, including IL6 and IL7, as
well as TNF-related proteins, in plasma samples from women actively ill
with AN, women recovered from AN (AN-REC), and normal weight
healthy controls (CTRL).
2. Materials and methods
2.1. Participants
The study participants were identified from the Swedish sample of
the Anorexia Nervosa Genetics Initiative (ANGI-SE). Details on the re-
cruitment procedure were described previously (Thornton, 2018). The
general inclusion criteria for the AN group for this study were female
patients, at least 18 years of age, meeting DSM-IV criteria for AN, with
the exception of amenorrhea (Association, 1994), with at minimum one
year since AN onset (n = 113). AN with binge eating (AN-BE) was de-
fined by documented episode(s) of binge eating during the last two
years before blood sampling. AN with past binge eating (AN-pBE) by
more than two years since last documented binge eating episode, and
AN without episodes of binge eating (AN-nonBE) by complete absence
of documented binge eating episodes. For AN-REC the inclusion criteria
were history of DSM-IV AN with subsequent weight restoration
(BMI greater than 20 kg/m2) plus no eating disorder behaviours for at
least a year (n = 114). The age-matched normal-weight female controls
reported no history of disordered-eating behaviour (CTRL, n = 113).
See table 1 for further information on the participants.
The study was approved by the Regional Ethics Review Board in
Stockholm. All participants provided written informed consent.
2.2. Blood sampling
Blood was collected using EDTA tubes at the hospital nearest to the
participant, sent to Karolinska Institutet Biobank with overnight mail,
and processed upon arrival. After centrifugation, plasma samples were
stored at −80 °C until shipping to Olink Proteomics (Uppsala, Sweden)
for analysis.
2.3. Proximity extension assay
The samples were analyzed with the inflammation reagent kit from
Olink Proteomics consisting of 92 preselected proteins, all related to
inflammation (Supplementary Table 1). The kit is based on the proxi-
mity extension assay (PEA) technology utilizing oligonucleotide labeled
antibody probe pairs binding to their respective target protein and a
proximity dependent DNA polymerization step, resulting in a reporter
sequence that can be quantified by real-time PCR (Assarsson, 2014).
Limit of detection (LOD) was reported by OLINK for each assay.
2.4. Statistical analyses
Given the highly non-normal distribution of several markers,
median and inter-quartile range (IQR) of clinical characteristics and
marker levels were calculated. All plasma marker concentrations were
analysed in the NPX unit, a log2-transformed normalized protein ex-
pression unit. Values below the LOD were treated as missing values.
Normality was assessed visually using quantile–quantile plots for all
markers. To rule out single sample multi-dimensional outliers, sample
scores from a principal component analysis (PCA) were computed to
summarize the combined proteomic variance and were assessed vi-
sually. Differences between groups (AN, AN-REC, and CTRL, as well as
between AN-BE, AN-pBE- or AN-nonBE) and associations with BMI
were assessed. To facilitate comparisons with studies that do not in-
clude patients with low BMI, as well as to assess whether the association
with BMI was linear over the whole range, associations with current
BMI were reported over the whole range, as well as separately for the
AN group (BMI < 18.5) and the non-AN group (BMI ≥ 18.5).
For normally distributed plasma marker variables, group differences
were assessed using ANOVA followed by post-hoc Tukey HSD test to
evaluate pairwise comparisons. The associations between marker levels
and BMI were assessed using linear regression with age as a covariate.
For variables with non-normal distributions, group differences were
assessed using Kruskal-Wallis test followed by post-hoc Dunn’s test to
evaluate pairwise comparisons. The associations between the median
marker levels and BMI were assessed using quantile regression with age
as a covariate. As a further post-hoc analysis, given the highly skewed
distribution of some of the markers, we assessed the differences in
distribution of values above the 90th percentile between the three
groups for all non-normal distributed markers. Marker levels were bi-
narized in two groups according to the 90th percentile cutoff and
Table 1
Sex, age, BMI, years since AN onset, and binge behavior of the study partici-
pants by group.
Characteristics AN AN-REC CTRL
n 113 113 114

















Years since AN onset
(median [IQR])
10.8 (6.0–15.0) 10.7 (6.0–14.0) -
AN with binge episode(s)
n (%);
current 26 (23.0%) - -
past 14 (12.4%) - -
never 53 (46.9%) - -
information not
available
20 (17.7%) - -
AN = anorexia nervosa, AN-REC = recovered from anorexia nervosa,
CTRL = healthy controls, IQR = interquartile range.
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differences in frequencies between groups were assessed using Chi-
square test. Correlations between protein markers were assessed using
Spearman correlations and partial Spearman correlations. To analyze
structural variation across the full panel, a partial least squares dis-
criminant analysis (PLS-DA) (Brereton and Lloyd, 2014; Wold et al.,
2001) model was computed. Permutation tests, in which the predictive
performance metric (Q2Y) of the model is tested against n models
trained on a permutated response variable, were used to avoid over-
fitting and indicate significance (Szymanska et al., 2012). Root mean
squared error of estimate (RMSEE) was reported.
Statistical analyses were conducted using R programming language
version 3.6.1 (including packages quantreg (Koenker, 2019); emmeans
and multcomp (Hothorn et al., 2008), and ropls v.1.8.0 (Thevenot et al.,
2015) for PCA And PLS). Graphs were built using ggplot2 (Wickham,
2016). In order to avoid overcorrection given the high correlation be-
tween some markers violating the assumption of test independence, we
estimated the number of effective tests Meff as described by Cheverud
and Nyholt et al (Cheverud, 2001; Nyholt, 2004). We adjusted p-values
to account for the 71 independent tests (total number of proteins tested:
74) using Bonferroni correction; an alpha level of 0.00070 was there-
fore considered statistically significant.
3. Results
Clinical characteristics of the study population are summarized in
Table 1. Eighteen proteins (Il17A, IL20RA, IL-1α, IL2, TSLP, FGF-5,
IL22RA1, IL24, IL13, ARTN, TNF, IL20, IL33, IFNγ, IL4, LIF, NRTN, and
IL5) were excluded from further analyses since more than 20% of the
data were missing (Supplementary Table 1). No individual had more
than three missing values in the remaining 74 proteins. A PCA model
for data overview retained 33.5% of the variance over the first three
components, and no major multi-dimensional outliers were detected in
this model. High correlations were observed between many of the
markers in all combined study participants. While most were positive,
one pair (TRANCE/RANKL) showed a high negative correlation
(Supplementary Fig. 1).
3.1. Inflammatory markers and AN
After Bonferroni correction, 25 significant differences were ob-
served between AN and CTRL, while 15 significant differences were
observed between AN and AN-REC (Fig. 1, Supplementary Table 2).
Separate graphs for all tested markers are provided in the supplement
(Supplementary Graphs). Nineteen proteins had lower plasma con-
centrations in AN compared with CTRL (ADA, CCL19, CD40, CD5,
CD8A, CSF1, CXCL1, CXCL5, HGF, IL10RB, IL12B, 1L18R1, LAP TGFß1,
MCP3, OSM, TGFα, TNFRSF9, TNFS14, and TRANCE), most of which
also differered significantly between AN and AN-REC (ADA, CD40,
CD5, CSF1, HGF, IL10RB, IL12B, 1L18R1, LAP TGFß1, TGFα, and
TRANCE). Six proteins were significantly higher in AN compared with
CTRL (CCL11, CCL25, CST5, DNER, LIFR, and OPG), three of which
(CCL11, CCL25, and LIFR) were also higher in AN than AN-REC. GDNF
was siginificantly higher in AN than AN-REC, but did not differ between
AN and CTRL. No significant differences were found between AN-REC
and CTRL (Fig. 1A).
Given the highly skewed distribution of some of the markers, we
evaluated whether there was a difference in distribution for values
above the 90th quantile between the three groups for all non-normally
distributed proteins. After correction for multiple testing, only IL6
showed a significant difference, with 22/34 of the 10% highest IL-6
values being measured in patients of the AN-group (χ2(2) = 20.03,
padj = 3.17 × 10-3).
No significant differences were seen between AN-BE, AN-pBE, or
AN-nonBE (data not shown).
3.2. Inflammatory markers and BMI
Fig. 1B shows that 25 proteins correlated positively with BMI (ADA,
AXIN1, CASP8, CD5, CD40, CSF1, CXCL1, CXCL5, EN-RAGE, HGF, IL6,
IL10RB, IL12B, IL18, IL18R1, LAP TGFß1, OSM, SIRT2, STAMBP,
TGFα, TNFRSF9, TNFS14, TRANCE, TRAIL, and VEGFA) while four
proteins correlated negatively with BMI (CCL11, CCL25, CCL28, and
DNER) (Supplementary Table 3, Supplementary Graphs). For most of
the proteins that were positively correlated with BMI, a correlation with
BMI among normal weight (BMI ≥ 18.5) participants could also be
seen. However, none of the proteins for which higher concentrations in
AN and/or a negative association with BMI were reported (i.e., CCL11,
CCL25, CCL28, CST5, DNER, GDNF, LIFR, and OPG) showed any as-
sociation with BMI among only normal weight individuals. Only one
protein, CCL11, was significantly negatively associated with BMI in
individuals with a BMI < 18.5.
Although CCL28, CDCP1, FGF21, IL6, STAMBP, and VEGFA were
strongly correlated with BMI, no group differences were observed for
these proteins.
3.3. Sensitivity analysis
As a sensitivity analysis, calculations were repeated replacing the
missing values by the LOD for the proteins that had up to 20% missing
values (MCP-3, GDNF, IL-17C, IL-2RB, FGF-23, IL-10RA and FGF-21).
Similar results regarding groups and BMI were observed.
3.4. Multivariate analysis
A PLS-DA model (2 components, Q2Y = 0.22, RMSEE = 0.409)
discriminated AN from AN-REC and CTRL with significant statistics
(p = 0.01) over 100 iterations of permutation testing (Supplementary
Figure 2)
4. Discussion
We analysed the hitherto largest battery of inflammatory markers in
plasma from women with active AN (N = 113), women who had re-
covered from AN (AN-REC, N = 113), and healthy female normal-
weight controls (N = 114). We found a markedly different proteomic
plasma profile of inflammatory markers in women with active AN
compared not only with controls, but also compared with women who
had recovered from AN. Several of these proteins were negatively or
positively correlated with BMI, mostly in line with the differences ob-
served between the study groups (see further discussion below).
Importantly, we found no differences between women who had re-
covered from AN and controls, not even in a multivariate PLS-DA
model. This suggests that aberrant inflammatory profile is a state
marker associated with active AN and/or low BMI.
4.1. Associations between plasma markers and AN
The majority of our observations have not been reported previously.
Of the proteins that were higher in AN compared to CTRL and/or AN-
REC (CCL11, CCL25, CST5, DNER, GDNF, LIFR and OPG), LIFR
(Monteleone et al., 1999) and OPG has previously been reported to be
higher in AN than controls (Golabek, 2015; Ohwada et al., 2007; Misra,
2003; Ostrowska, 2016). Of the proteins that were lower in AN than
controls (ADA, CCL19, CD40L, CD5, CD8A, CSF-1, CXCL1, CXCL5, HGF,
IL10RB, IL12B, 1L18R1, LAP-TGFß 1, OSM, TGFα, TNFRSF9, TNFSF14
and TRANCE), lower TGFß has previously been reported (Ostrowska,
2016), but not in all reports (Solmi, 2015). Our finding of lower CSF1
plasma levels in AN accords a previous report of reduced CSF1 in the
supernatant of peripheral blood mono-nuclear cells from AN (Vaisman,
1996). However, we found lower plasma levels of TRANCE in AN,
which conflicts two previous studies that reported higher concentration
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Fig. 1. Plasma protein concentrations changed in AN vs AN-REC and CTRL (A), and associations between plasma protein concentrations and BMI (B). Values are
normalized protein expression (NPX) values in log2 scale. AN = anorexia nervosa, AN-REC = recovered from anorexia nervosa, CTR = normal weight healthy
control. For full protein names see Table S1.
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in AN than controls (Golabek, 2015; Ostrowska, 2016). A discussion on
the proteins that were associated with AN-status and/or BMI at a sig-
nificance threshold of p < 0.01 can be found in the Supplement. Al-
though we did not see any differences within active AN cases with re-
gards to history of binge-eating behavior, our results need replication
and should be interpreted with care.
The previous most frequently documented changes in AN with re-
gard to inflammatory markers in blood are high levels of IL6 and TNFα
(Solmi, 2015; Dalton, 2018; Dalton, 2018). We did not find higher IL6
concentration in AN. In fact, we observed a positive association be-
tween median plasma levels of IL6 and BMI. However, when analyzing
the distribution of the patients with values above the 90th percentile for
IL6 levels, 22 of 34 cases in fact belonged to the AN group. Spec-
ulatively, these could represent a subgroup of AN patients (e.g., re-
cently physically active patients) that if overrepresented in a cohort
could lead to higher mean IL6 concentrations in an AN group (Pedersen
and Febbraio, 2008). TNFα was unfortunately excluded from our study
since 69% of data was missing. Several other proteins that sporadic
previous studies have found altered in AN (e.g., IL7 (Germain, 2016),
VEGFA (Dalton, 2018), CXC3L1 (Zhang et al., 2017) did not replicate in
our sample.
There is a bidirectional relationship between inflammation and food
intake. On the one hand, reduced food intake is a common symptom of
sickness behavior (Dantzer et al., 2008) and several cytokines have
been shown to be anorexigenic (Gautron and Layé, 2010). On the other
hand, increased (e.g., obesity) as well as reduced body weight (e.g.,
malnutrition, wasting) have been associated with changes in in-
flammatory status (Gibson and Mehler, 2019; de Heredia et al., 2012).
While obesity is a proinflammatory state, reduced body weight seems to
have a more complex impact on the immune system and might differ
depending on the cause of weight loss; malnourished patients are at
increased risk for infections whereas AN patients are not (Gibson and
Mehler, 2019; Bowers and Eckert, 1978). From this perspective, a study
comparing inflammatory markers in other populations characterized by
low BMI (e.g., constitutional thinness, other medical conditions marked
by low weight) would be informative.
4.2. Associations between plasma markers and BMI
Several of the associations with BMI that we found have been pre-
viously reported (ADA, CD40, CSF1, CXCL5, HGF, IL10RB, LAP-TGFß,
OSM, TGFα, TNFRSF9, IL18, SIRT2), but we also report several novel
associations (CD4, IL12B, TNFSF14, TRANCE, AXIN1, CASP8, EN-
RAGE, TRAIL). Separate posthoc correlation analyses below and above
BMI 18.5 revealed that some associations were mainly driven by in-
dividuals with very low BMI. This means that studies that do not in-
clude indivduals with very low BMI are less likely to detect such cor-
relations. Interestingly, many of the proteins we find to be associated
with BMI have previously been shown to be functionally involved in
weight gain or loss in experimental animal models, such as CSF1 (Wei,
2005), CCL19/CCR7 signalling (Sano, 2015), CXCL1 (Pedersen et al.,
2012), TNFRSF9 (Kim, 2011), TNFSF14 (Saunders, 2018), TRANCE (Yi,
2017), CX3CL1 (Dorfman, 2017; Morari, 2014), TGFα (Luetteke et al.,
1993), DNER (Park, 2010), GDNF (Mwangi, 2014; Tumer, 2006;
Manfredsson, 2009), LIF/LIFR (Plata-Salaman, 1996; Arora, 2018),
IL18/IL18R1 (Murphy, 2016). For further discussion, see the
Supplement.
4.3. Inflammatory markers and bone physiology
Some proteins included in the OLINK panel have other physiological
roles not directly linked to inflammation. For example, we found that a
subgroup of proteins involved in bone physiology differed between AN
and controls, including OPG, TRANCE (RANKL), CSF1 (MCSF), LAP-
TGFß, and CST5. Low bone mineral density and increased risk of
fractures is a common complication of AN (Steinman and Shibli-Rahhal,
2019). Several factors have been suggested as being causative, in-
cluding decreased estrogen, low BMI, elevated cortisol, low IGF1, as
well as poor nutrition and a lack of vitamin D (Steinman and Shibli-
Rahhal, 2019). Although there is some evidence that body weight re-
storation can reverse bone loss (Hubel, 2019), not all studies have
shown this effect (Reviewed by Steinman and Shibli-Rahhal, 2019). Our
results indicate a disturbed balance between bone formation and re-
sorption in acute AN. Importantly, none of the proteins involved in
bone physiology differed between AN-REC and controls, suggesting that
these effects are reversed upon weight gain/-restoration. However,
longitudinal studies are needed for confirmation.
4.4. Strengths and limitations
Previous studies on inflammatory markers in AN are scarce and
typically investigate a limited set of inflammatory markers in small
samples. Furthermore, most previous studies have not included a re-
covered AN group, which precludes any conclusions as to whether al-
tered inflammatory profile is a state or trait marker in AN. We in-
vestigated a broad array of inflammatory markers in a large sample of
individuals with AN. We not only included a control group matched for
age, but also an age-matched group with women who had recovered
from AN. Even though our study would support the state hypothesis for
most markers—as no differences between AN-REC and CTRL were
seen—a longitudinal study following people with AN across the course
of recovery is necessary to confirm our findings. Hence, one limitation
is that our study was cross-sectional and cannot establish cause and
effect. Another limitation is the blood sampling procedure, as blood
samples were sent via overnight mail before being processed. One study
found that a 24 h pre-centrifugation delay significantly affected certain
plasma protein concentrations, including 22 proteins analysed in this
paper. 4EBP1, ADA, AXIN1, CASP8, CD6, CXCL1, CXCL5, CXCL6,
CXCL11, EN-RAGE, HGF, IL7, IL18, LAP-TGFß, MCP2, MCP3, MCP4,
MMP1, OSM, STAMBP, TGFα, and TNFSF14 have been shown to be
significantly higher after 24 h at room temperature compared with
direct centrifugation (Shen, 2018). Even if this is likely to have in-
troduced noise and effectively reduced power, it is unlikely to have
affected group differences since all samples were collected and handled
in the same way. Further, we lack information on time of day of sam-
pling, which would have been valuable as some inflammatory markers
vary with circadian rhythms (Wipfler, 2013). Finally, we lack some
phenotypic information that may influence cytokine concentrations
(O'Connor, 2009) such as drug use (including illicit drugs), smoking,
exercise, sleep, ethnicity, socioeconomic and hormonal status, psy-
chiatric as well as somatic comorbidities such as autoimmune/in-
flammatory diseases.
In conclusion, we observed an aberrant inflammatory plasma profile
in AN, which was not seen in those who had recovered from AN. We
also observed that plasma concentrations of several of the inflammatory
proteins correlate with BMI. Although there are currently no data on
causal effects of inflammatory markers on AN, our results could be seen
as yet another reason to provide prompt and adequate treatment to
patients with AN. Further investigations on the long-term effects of an
aberrant inflammatory profile in AN are warranted.
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